Early-life stress caused by adverse childhood experiences (ACEs) has been linked to alterations in HPA axis activity that persist into adulthood, which may play a role in mental health disorders, including depression.
Kratom is used for symptoms of pain, anxiety, depression, and opioid withdrawal, and serious adverse events are uncommon.
There is an emerging view that sleep disorders are not merely symptoms of psychiatric conditions; instead there may be a complex, bidirectional relationship between psychiatric and sleep disorders.
Although emerging adults reported a higher prevalence of intravenous drug use and more severe employment, legal, and psychiatric problems at intake, they achieved dramatic improvements in response to interim buprenorphine treatment.
Psilocybin-assisted psychotherapy may promote long-term benefits in terms of reductions in anxiety, depression, and hopelessness among patients with cancer-related psychiatric distress.
For persons with a previous diagnosis of generalized anxiety disorder (GAD), factors associated with being in complete mental health (CMH) include female gender, older age, being married, and reporting good to excellent physical health.
Benzodiazepines are considered a third-line treatment for the management of anxiety and sleep disorders, after antidepressant medications and psychotherapy.
The FDA has granted Fast Track designation to PH94B (aloradine; VistaGen Therapeutics), a central nervous system neuroactive nasal spray for the on-demand treatment of social anxiety disorder.
By age 18, approximately 15% of the cohort had been diagnosed with a mental disorder.
While experiential avoidance may offer short-term relief from distress, in the long run it may allow psychopathological symptoms to persist, as individuals do not fully process their distress.
